<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_fncUDAb">Could serum zonulin be an intestinal permeability marker in diabetes kidney disease?</title>
				<funder>
					<orgName type="full">Conselho Nacional de Desenvolvimento Cientı ´fico e Tecnolo ´gico</orgName>
				</funder>
				<funder>
					<orgName type="full">Hospital de Clı ´nicas de Porto Alegre</orgName>
				</funder>
				<funder>
					<orgName type="full">CNPq</orgName>
				</funder>
				<funder ref="#_JA5nt9y">
					<orgName type="full">Fundo de Incentivo à Pesquisa e Eventos</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
					<p type="raw">© 2021 Carpes et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p>
				</availability>
				<date type="published" when="2021-06-25">June 25, 2021</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Larissa</forename><forename type="middle">Salomoni</forename><surname>Carpes</surname></persName>
							<idno type="ORCID">0000-0002-0818-5383</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Faculty of Medicine , Post Graduate Program in Food, Nutrition and Health , Universidade Federal do Rio Grande do Sul , Porto Alegre , Rio Grande do Sul , Brazil ,</note>
								<orgName type="department" key="dep1">Faculty of Medicine</orgName>
								<orgName type="department" key="dep2">Post Graduate Program in Food</orgName>
								<orgName type="department" key="dep3">Nutrition and Health</orgName>
								<orgName type="institution">Universidade Federal do Rio Grande do Sul</orgName>
								<address>
									<addrLine>Porto Alegre</addrLine>
									<settlement>Rio Grande do Sul</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bruna</forename><forename type="middle">Bellincanta</forename><surname>Nicoletto</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Life Sciences Knowledge Area , Universidade de Caxias do Sul , Caxias do Sul , Rio Grande do Sul , Brazil ,</note>
								<orgName type="department">Life Sciences Knowledge Area</orgName>
								<orgName type="institution">Universidade de Caxias do Sul</orgName>
								<address>
									<addrLine>Caxias do Sul</addrLine>
									<settlement>Rio Grande do Sul</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Luis</forename><forename type="middle">Henrique</forename><surname>Canani</surname></persName>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Faculty of Medicine , Post Graduate Program in Medical Sciences: Endocrinology , Universidade Federal do Rio Grande do Sul , Porto Alegre , Rio Grande do Sul , Brazil ,</note>
								<orgName type="department" key="dep1">Faculty of Medicine</orgName>
								<orgName type="department" key="dep2">Post Graduate Program in Medical Sciences: Endocrinology</orgName>
								<orgName type="institution">Universidade Federal do Rio Grande do Sul</orgName>
								<address>
									<addrLine>Porto Alegre</addrLine>
									<settlement>Rio Grande do Sul</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Endocrine Division , Hospital de Clı ´nicas de Porto Alegre , Porto Alegre , Brazil ,</note>
								<orgName type="department">Endocrine Division</orgName>
								<orgName type="institution">Hospital de Clı ´nicas de Porto Alegre</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jakeline</forename><surname>Rheinhemer</surname></persName>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Faculty of Medicine , Post Graduate Program in Medical Sciences: Endocrinology , Universidade Federal do Rio Grande do Sul , Porto Alegre , Rio Grande do Sul , Brazil ,</note>
								<orgName type="department" key="dep1">Faculty of Medicine</orgName>
								<orgName type="department" key="dep2">Post Graduate Program in Medical Sciences: Endocrinology</orgName>
								<orgName type="institution">Universidade Federal do Rio Grande do Sul</orgName>
								<address>
									<addrLine>Porto Alegre</addrLine>
									<settlement>Rio Grande do Sul</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Daisy</forename><surname>Crispim</surname></persName>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Faculty of Medicine , Post Graduate Program in Medical Sciences: Endocrinology , Universidade Federal do Rio Grande do Sul , Porto Alegre , Rio Grande do Sul , Brazil ,</note>
								<orgName type="department" key="dep1">Faculty of Medicine</orgName>
								<orgName type="department" key="dep2">Post Graduate Program in Medical Sciences: Endocrinology</orgName>
								<orgName type="institution">Universidade Federal do Rio Grande do Sul</orgName>
								<address>
									<addrLine>Porto Alegre</addrLine>
									<settlement>Rio Grande do Sul</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Endocrine Division , Hospital de Clı ´nicas de Porto Alegre , Porto Alegre , Brazil ,</note>
								<orgName type="department">Endocrine Division</orgName>
								<orgName type="institution">Hospital de Clı ´nicas de Porto Alegre</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gabriela</forename><surname>Corrêa Souza</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Faculty of Medicine , Post Graduate Program in Food, Nutrition and Health , Universidade Federal do Rio Grande do Sul , Porto Alegre , Rio Grande do Sul , Brazil ,</note>
								<orgName type="department" key="dep1">Faculty of Medicine</orgName>
								<orgName type="department" key="dep2">Post Graduate Program in Food</orgName>
								<orgName type="department" key="dep3">Nutrition and Health</orgName>
								<orgName type="institution">Universidade Federal do Rio Grande do Sul</orgName>
								<address>
									<addrLine>Porto Alegre</addrLine>
									<settlement>Rio Grande do Sul</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>5</label> Food and Nutrition Research Center , Hospital de Clı ´nicas de Porto Alegre , Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil</note>
								<orgName type="department" key="dep1">Food and Nutrition Research Center</orgName>
								<orgName type="department" key="dep2">Hospital de Clı ´nicas de Porto Alegre</orgName>
								<orgName type="institution">Universidade Federal do Rio Grande do Sul</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<note type="raw_affiliation">Universita degli Studi di Perugia , ITALY</note>
								<orgName type="institution">Universita degli Studi di Perugia</orgName>
								<address>
									<country key="IT">ITALY</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_3aj5drG">Could serum zonulin be an intestinal permeability marker in diabetes kidney disease?</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2021-06-25">June 25, 2021</date>
						</imprint>
					</monogr>
					<idno type="MD5">132F748526801331D146A3B95BE5BBEB</idno>
					<idno type="DOI">10.1371/journal.pone.0253501</idno>
					<note type="submission">Received: January 7, 2021 Accepted: June 6, 2021</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T08:29+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_g2bXC8J"><p xml:id="_AkdtU2d"><s xml:id="_j9ZDnzD">Zonulin is a protein associated with the tight junction complex opening at the intestinal epithelium, previously linked to obesity, cardiovascular diseases, type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD).</s><s xml:id="_kpsCFKF">However, its role in CKD has not been totally elucidated.</s><s xml:id="_BzG9M9v">This study aimed to evaluate zonulin levels in subjects with diabetic kidney disease (DKD).</s><s xml:id="_GTsm3RV">This case-control study included two cases groups: 1) Advanced DKD cases: T2DM patients with estimated glomerular filtration rate (eGFR) &lt;60ml/min/1.73m 2 ; 2) Albuminuric T2DM cases: diabetic patients with urinary albumin excretion (UAE) &gt;30mg/g creatinine, but with eGFR&gt;60ml/min/1.73m 2 .</s><s xml:id="_ywMquJ4">Two control groups were also included: 1) T2DM controls: patients with T2DM without impaired kidney function; 2) Non-T2DM controls: subjects without T2DM and normal renal function.</s><s xml:id="_jvMjuNe">Serum levels of zonulin were measured by ELISA.</s><s xml:id="_9DQGxNA">Eighty-six individuals were included.</s><s xml:id="_n5qCMAz">Zonulin levels was different among study groups (P = 0.003).</s><s xml:id="_sjz3uyu">T2DM controls presented higher zonulin levels than non-T2DM controls [(131.35</s><s xml:id="_6tUnb8Q">(83.0-170.5)</s><s xml:id="_Y8XyD7s">vs. 87.25 (54.7-111.8),</s><s xml:id="_uMQYn5Q">P = 0.018] and advanced DKD cases [63.72 (45.03-106.0);</s><s xml:id="_vC2H73h">P = 0.007].</s><s xml:id="_3E9E3Wf">Zonulin showed a positive correlation with eGFR (r = 0.222; P = 0.040), total cholesterol (r = 0.299; P = 0.034), LDL (r = 0.258; P = 0.021), and negative with albuminuria (r = -0.243;</s><s xml:id="_C4x9Cny">P = 0.024) and body fat (r = -0.271;</s><s xml:id="_Sp9X9yN">P = 0.014).</s><s xml:id="_sw4GvFa">In the multivariate logistic regression analyses, zonulin levels were independently associated to renal outcomes [OR 0.99 (0.98-0.99,</s><s xml:id="_aTV73Ep">P = 0.012)] after 5-year inclusion.</s><s xml:id="_2RJGs49">In conclusion, increased zonulin levels in patients with TD2M without renal disease suggest an impaired intestinal permeability.</s><s xml:id="_qbf9JAy">Moreover, its association with renal outcomes could indicate its use as a disease monitoring marker.</s><s xml:id="_mNtg3Mr">However, the mechanisms behind this association should be better understood.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_uU2Brh4">Introduction</head><p xml:id="_fSS4Zh4"><s xml:id="_5PCx9T5">The intestinal microbiota has been studied in several pathologies, including type 2 diabetes mellitus (T2DM) <ref type="bibr" target="#b0">[1]</ref> and chronic kidney disease (CKD) <ref type="bibr" target="#b1">[2]</ref>.</s><s xml:id="_aq3Upkx">In both cases, a reduction in intestinal beneficial bacteria and a proliferation of pathogenically bacteria have been suggested, characterizing a condition named dysbiosis <ref type="bibr" target="#b2">[3]</ref>.</s><s xml:id="_pUykAEs">Besides this unbalance in microbiota patients with advanced CKD have an incremental in microbial urease enzyme, which is responsible for transforming excess urea into ammonia in the gut <ref type="bibr" target="#b3">[4]</ref>.</s></p><p xml:id="_6AQs9hu"><s xml:id="_2Zyve2Z">Both dysbiosis and ammonia accumulation have an impact in intestinal permeability and CKD progression <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref>.</s><s xml:id="_Sh2sxan">An impaired gut barrier presents a systemic inflammation pattern which allows bacteria translocation and other pathogens into the circulation <ref type="bibr" target="#b6">[7]</ref>.</s><s xml:id="_rAajAcm">Several factors influence the intestinal barrier and permeability, such as microbiota, diet, use of some medications, alcohol consumption, and smoking <ref type="bibr" target="#b7">[8]</ref>.</s></p><p xml:id="_2jbA6Vc"><s xml:id="_y33ySAM">Zonulin is a family peptide produced in the intestinal and hepatic cells that regulates a protein complex named tight junctions <ref type="bibr" target="#b8">[9]</ref>.</s><s xml:id="_ymTH3eS">Higher levels of zonulin have been associated with increased intestinal permeability since it induces disruption between the junctions in the epithelial intestine cells <ref type="bibr" target="#b9">[10]</ref>.</s><s xml:id="_BVFWEHJ">Zonulin is mostly stimulated by bacteria and gluten protein (gliadin), making the intestine permeable by opening enterocytes <ref type="bibr" target="#b10">[11]</ref>.</s></p><p xml:id="_jTKn3zK"><s xml:id="_Ca9DusP">Studies regarding zonulin as a marker of intestinal permeability have been associated with several diseases <ref type="bibr" target="#b11">[12]</ref>.</s><s xml:id="_K33uDu8">As far as we know, some conditions were linked to increased zonulin levels, representing their associations with an impaired gut permeability <ref type="bibr" target="#b12">[13]</ref>.</s><s xml:id="_RWMv5SR">Non-coeliac gluten sensitivity <ref type="bibr" target="#b13">[14]</ref>, inflammatory bowel syndrome <ref type="bibr" target="#b14">[15]</ref>, nkylosing spondylitis <ref type="bibr" target="#b15">[16]</ref> and arthritis <ref type="bibr" target="#b16">[17]</ref> also have been linked to changes in intestinal permeability.</s><s xml:id="_MWVJVm8">Besides that, non-communicable diseases, such as obesity <ref type="bibr" target="#b17">[18]</ref> and cardiovascular diseases <ref type="bibr" target="#b18">[19]</ref> were correlated to zonulin levels.</s></p><p xml:id="_D2DjhJh"><s xml:id="_MptrRD8">T2DM <ref type="bibr" target="#b19">[20]</ref> and CKD <ref type="bibr" target="#b20">[21]</ref> also have been associated to serum zonulin, but little is known about zonulin and diabetic kidney disease (DKD).</s><s xml:id="_PttXKXs">Additionally, there are inconsistences according to the studies' results.</s><s xml:id="_fhuNnJD">Therefore, this study aimed to evaluate zonulin serum levels in DKD patients compared to healthy and diabetic subjects without kidney disease.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_c2Jn5PB">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_YJ7xGSf">Design and patients</head><p xml:id="_RVj8V4K"><s xml:id="_uhscvmh">The study design was previously described elsewhere <ref type="bibr" target="#b21">[22]</ref>.</s><s xml:id="_3wRpa8m">Subjects attending to an Endocrinology outpatient clinic at the Hospital de Clı ´nicas de Porto Alegre were invited to this casecontrol study.</s><s xml:id="_Zr93qFn">Recruitment date ranged between October 2013 and November 2014 and was based on renal function and T2DM diagnosis.</s><s xml:id="_yvF2UV8">Two case groups were included: 1) Advanced DKD cases: T2DM patients with estimated glomerular filtration rate (eGFR) &lt;60 mL/min/ 1.73m 2 , and 2) Albuminuric DKD cases: T2DM patients with urinary albumin excretion (UAE) � 30 mg/g creatinine and eGFR �60 mL/min/1.73m 2 .</s><s xml:id="_sQYMCrJ">Once cases were included, controls were sought based on similar age, gender and body mass index (BMI) and were divided into two control groups: 1) T2DM controls: patients with T2DM with UAE &lt;30 mg/g creatinine and eGFR �60 mL/min/1.73m 2 , and 2) Non-T2DM controls: individuals without diabetes and eGFR �60 mL/min/1.73m 2 .</s><s xml:id="_j2ZnfFR">Exclusion criteria used in the original study were age below 18 years, cancer, pancreatitis, dialysis, acute infection, previous transplantation, pregnancy, and alcohol or drug abuse.</s><s xml:id="_MwpeXTg">The present study also excluded patients with non-authorization data for new studies, with inflammatory bowel diseases and those with serum zonulin greater than 400ug/dL (because limitation in the assay).</s></p><p xml:id="_XJzHTEG"><s xml:id="_EFqTpFJ">Diabetes was defined according to American Diabetes Association criteria <ref type="bibr" target="#b22">[23]</ref> and renal function was estimated using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula <ref type="bibr" target="#b23">[24]</ref>.</s><s xml:id="_zDEZaRK">The study was approved by the Ethics Committee of the Hospital de Clı ´nicas de Porto Alegre, and all subjects gave informed written consent before participation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_fZnzfEK">Clinical, anthropometric and biochemical data evaluation</head><p xml:id="_fArR36E"><s xml:id="_WUT9B2Y">Clinical and sociodemographic data were collected through questionnaires and electronical charts, and included age, gender, ethnicity, T2DM duration, hypertension, and medication use.</s></p><p xml:id="_a8J9fg7"><s xml:id="_qm8tCyP">Anthropometric evaluation consisted of weight and height measured in anthropometric scale with a stadiometer, for later body mass index (BMI) estimation.</s><s xml:id="_bss4pvW">Body composition was evaluated by an electric bioimpedance (InBody 230; Biospace, Seul, Korea).</s><s xml:id="_za8eV2F">All measures were made while fasting, light clothes and without shoes <ref type="bibr" target="#b24">[25]</ref>.</s></p><p xml:id="_Mk5Muf7"><s xml:id="_aWMfeRy">Blood and spot urine tests were performed after 12-hour overnight fast.</s><s xml:id="_cKReRSA">Levels of fasting plasma glucose (Hexokinase UV enzymatic), HbA1c (HPLC), total cholesterol (enzymatic colorimetric), HDL-cholesterol (homogeneous enzymatic colorimetric), triglycerides (TG) (enzymatic colorimetric), high-sensitivity C-reactive protein (hsCRP) (immunoturbidimetry), albuminuria (immunoturbidimetry), and serum creatinine (Jaffe method) were determined using standardized techniques.</s><s xml:id="_A5jhEbE">LDL-cholesterol was calculated according to Fridelwald formula: LDL-c = total cholesterol-(HDL-cholesterol + triglycerides / 5), when TG was below 400 mg/mL.</s><s xml:id="_krSpjBG">Blood samples were collected, centrifuged and kept in storage at -80˚C for zonulin and interleukin-6 (IL-6) analysis.</s><s xml:id="_JppuP3p">Zonulin concentration was quantified in serum samples, using the haptoglobin (encoded HP; Hp2-Alpha; Alpha-2-Macroglobulin; Zonulin) concentration assessed by ELISA (Cloud-Clone Corp, Katy, TX).</s><s xml:id="_88GctaC">The assay sensitivity was 2.92 ng/mL and assay range was 6.25-400 ng/mL, while inter-assay variability was less than 12% for serum samples.</s><s xml:id="_hFPYQx4">All zonulin samples were analyzed in duplicates.</s><s xml:id="_ESVyDd6">IL-6 concentration was determined in serum samples, using Human IL-6 Quantikine ELISA kit (R&amp;D Systems, Minneapolis, MN, USA).</s><s xml:id="_gUdCAWP">Only 30.7% samples were analyzed in duplicates.</s></p><p xml:id="_fJ3exMW"><s xml:id="_gszg3uQ">After 5 years of study inclusion, outcomes of each patient were assessed through medical online records or by phone call when no information was available.</s><s xml:id="_5DkYrZG">The evaluated outcomes were: decline in renal function (defined by change in stage of CKD: yes or no), onset dialysis or renal transplantation, stroke, myocardial infarction, coronary procedures (percutaneous coronary intervention and myocardial revascularization surgery), and death.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_xmAy8j4">Statistical analysis</head><p xml:id="_uvvuMm6"><s xml:id="_HpKYvYw">Data were analyzed through the Statistical Package for Social Sciences, version 18.0 (SPSS Inc, Chicago, IL).</s><s xml:id="_4JvKNVP">Continuous variables were tested for normality by Shapiro-Wilk test.</s><s xml:id="_ZXsxUcA">Since zonulin concentrations presented asymmetric distribution, this variable was logarithmically transformed before analysis.</s><s xml:id="_N6vBnE4">Comparisons between groups were performed using Chi-Square, One-Way ANOVA with Levene and Tukey or Kruskal-Wallis with Dunn tests, when appropriate.</s><s xml:id="_3myqN7R">Correlations were tested by Pearson's or Spearman's correlation coefficient, according to variable distribution.</s><s xml:id="_yGQhevt">Significant variables from the correlations and that were not used in T2DM and CKD diagnosis were applied to correct zonulin levels by a regression model.</s><s xml:id="_KACGhSd">These variables were LDL and body fat percentage.</s><s xml:id="_QTEbTpz">Then, adjusted zonulin levels were compared among groups using ANCOVA with Bonferroni test.</s><s xml:id="_h8qsDNb">For this analysis, zonulin log values were used, but data presented in the result section are described as median for better understanding of the findings.</s><s xml:id="_NGJ5aBg">Zonulin levels were compared between patients who have or not have outcomes at 5 years after study inclusion through Student's t test.</s><s xml:id="_5XyxNP2">Multivariable Poisson regression analysis was performed to identify the association of zonulin and presence of renal outcomes, adjusted for T2DM, dyslipidemia, smoking, obesity and age, known as possible risk factors to higher intestinal permeability <ref type="bibr" target="#b12">[13]</ref>.</s><s xml:id="_B23SaJG">The level of statistical significance was established as 5%.</s></p><p xml:id="_rSxFRSN"><s xml:id="_VarKwbH">Sample size calculation was based on a previous study <ref type="bibr" target="#b25">[26]</ref> considering a standard deviation = 4, size effect = 0.54, power of 95% and level of significance of 5%.</s><s xml:id="_w3BkfGJ">The total sample estimated was 56 subjects.</s><s xml:id="_KtarYRg">Because greater sample size was available from the previous study, we had a power of 99.6%.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_QmHB8b5">Results</head><p xml:id="_Yy5pSuW"><s xml:id="_KmbMA6Q">From 114 eligible patients from the previous study <ref type="bibr" target="#b21">[22]</ref>, 28 were excluded because their serum zonulin levels were greater than 400ug/dL or they did not consent to the new study, resulting in 86 patients included in the present analysis.</s></p><p xml:id="_PX8VVr9"><s xml:id="_6fNNgdh">The total sample was composed mostly by women (57%), with white ethnicity (67.4%) and the mean age was 61.2 ± 1.02 years.</s><s xml:id="_Mqaz3d5">Sociodemographic and clinical data among study groups are presented in Table <ref type="table">1</ref>.</s><s xml:id="_XrPGKAj">Age, gender, ethnicity, smoking, BMI, body fat, total cholesterol, and hsCRP were similar between groups.</s><s xml:id="_b3CSSA2">T2DM duration was also similar between groups with diabetes.</s><s xml:id="_Md9dVJQ">Advanced DKD cases presented worst HDL-cholesterol, triglycerides, and IL-6 levels.</s><s xml:id="_fm5EBEZ">Non-T2DM controls had lower hypertension prevalence and higher LDL-cholesterol levels (Table <ref type="table">1</ref>).</s></p><p xml:id="_BJDnKJf"><s xml:id="_H8engaA">Serum zonulin levels were significantly different among groups (P = 0.003) and are depicted in Zonulin presented a positive correlation with eGFR (r = 0.222; P = 0.040), total cholesterol (r = 0.299; P = 0.034), LDL (r = 0.258; P = 0.021), and negative with albuminuria (r = -0.243;</s><s xml:id="_jbRYwen">P = 0.024) and body fat (r = -0.271;</s><s xml:id="_MxUFxZT">P = 0.014) (Table <ref type="table">2</ref>).</s></p><p xml:id="_ytZ83rw"><s xml:id="_8Q7nZrC">Table 1.</s><s xml:id="_BVYz2TP">Sociodemographic, clinical, biochemical and anthropometric characteristics among groups.</s><s xml:id="_Cfh2EBJ">Non-T2DM control (n = 18) T2DM control (n = 26) T2DM albuminuric (n = 20) DKD (n = 22) P value Age (years) 59.50 ± 10.37 59.73 ± 9.15 64.05 ± 8.63 61.68 ± 9.99 0.391 Female, n (%) 11 (61.1) 14 (53.8) 13 (65.0)</s><s xml:id="_eUCkJsy">11 (50.0)</s><s xml:id="_gNe62zj">0.755 Caucasian, n (%) 11 (61.1)</s><s xml:id="_62zc6Aw">18 (69.2) 15 (75) 14 (63.6)</s><s xml:id="_6by2s3D">0.808 Non-smoker, n (%) 9 (50.0) 14 (53.8) 9 (45.0) 13 (59.1)</s><s xml:id="_JRz3eFx">0.540 T2DM duration (years) -15.57</s><s xml:id="_JMJzp8Z">± 9.49 14.3 ± 7.98 18.22 ± 9.24 0.353 Hypertension, n (%) 5 (33.3) a 25 (96.2) b 20 (100) b 22 (100) b &lt;0.001 eGFR (mL/min/1,73m 2 ) 100.0 (88.45-114.25) a 95.1 (85.38-116.25) a 98.0 (92.0-106.0)</s><s xml:id="_qKjKgbP">a 23.0 (17.0-33.64)</s><s xml:id="_B7CsU9D">b &lt;0.001 Albuminuria (mg/L) 7.40 (2.99-12.30)</s><s xml:id="_X8JW6jJ">a 11.70 (4.65-19.95) a 98.70 (61.30-209.97)</s><s xml:id="_bjmbFsJ">b 618.15 (200.15-1854.7)</s><s xml:id="_6U3AV8M">b &lt;0.001 Serum creatinine (mg/dL) 0.69 (0.58-0.87) a 0.73 (0.60-0.95) a 0.72 (0.55-0.84) a 2.51 (2.02-3.29)</s><s xml:id="_GCyxuga">b &lt;0.001 Fasting glucose (mg/dL) 90.0 (83.0-94.0) a 140.0 (113.75-169.50)</s><s xml:id="_jjzcSEx">b 162.0 (88.25-191.25)</s><s xml:id="_Sv7We9p">b 126.0 (73.0-171.5)</s><s xml:id="_gxKUR6Z">b &lt;0.001 HbA1c (%) 5.5 (5.3-5.7) a 7.85 (7.0-9.12)</s><s xml:id="_TpbhPSN">b 8.7 (7.6-9.4)</s><s xml:id="_S5R7Syw">b 7.9 (7.2-9.4)</s><s xml:id="_5eN9932">b &lt;0.001</s><s xml:id="_Jnm3GqY">Total Cholesterol (mg/dL) 200.28 ± 33.08 179.15 ± 48.28 179.40 ± 40.52 181.73 ± 53.03 0.413 HDL-Cholesterol (mg/dL) 45.67 ± 8.97 a 40.65 ± 7.71 a 38.75 ± 11.0 a 36.5 ± 10.48 b 0.026 LDL-Cholesterol (mg/dL) 125.8 (101.95-144.3) a 97.7 (72.4-136.1)</s><s xml:id="_uQfptDT">ab 94.0 (84.85-99.9)</s><s xml:id="_4PzNw6g">b 89.0 (72.0-122.5)</s><s xml:id="_ZkrZg7N">b 0.008 Triglycerides (mg/dL) 126.56 ± 51.55 a 156.69 ± 69.78 ab 253.05 ± 213.10 b 255.64 ± 177.42 b 0.007 hsCRP (mg/dL) 3.06 (1.72-9.29)</s><s xml:id="_tDxNDEg">3.44 (1.36-8.01)</s><s xml:id="_Qfcvzq4">2.66 (1.75-4.28)</s><s xml:id="_HvS8YZN">4.54 (1.81-17.52)</s><s xml:id="_x48ryxM">0.262 IL-6 (pg/dL) 3.12 (3.12-3.18) a 3.12 (3.12-3.5) a 3.12 (3.12-4.06) a 7.03 (3.94-9.66)</s><s xml:id="_8XZ7XKJ">b &lt;0.001 BMI (kg/m 2 ) 28.2 (25.5-33.0)</s><s xml:id="_kSvhZVH">30.0 (26.3-32.8)</s><s xml:id="_rRkc9r8">31.7 (27.7-38.1)</s><s xml:id="_4Ue5DXw">30.9 (28.0-38.5)</s><s xml:id="_pfqZ885">0.078 Body fat (%) 37.1 (29.5-43.5)</s><s xml:id="_NadGjp3">34.8 (28.0-42.7)</s><s xml:id="_2ZSmp3k">38.35 (23.7-46.1)</s><s xml:id="_zqDYw5x">38.25 (27.9-47.2) 0.700 Data expressed in n (%), median ± SD or median and interquartile range (P25 -P75).</s><s xml:id="_UPEnfrg">Different letters means p &lt;0.05.</s><s xml:id="_hHWvaB6">T2DM: Type 2 diabetes mellitus; HbA1c: Glycated hemoglobin; IL-6: Interleukin-6; BMI: Body mass index; hsCRP: High sensitivity C-reactive protein; eGFR: Estimated glomerular filtration rate.</s><s xml:id="_xv3rSHu"><ref type="url" target="https://doi.org/10.1371/journal.pone.0253501.t001">https://doi.org/10.1371/journal.pone.0253501.t001</ref></s></p><p xml:id="_5c5JwPK"><s xml:id="_s3VmPzq">After 5 years, 66 patients (76.7% of the sample) were evaluated for renal and cardiovascular outcomes and death.</s><s xml:id="_kQU4DAP">With respect to renal outcomes, 24 patients had renal function decline (39.3%), 10 patients started dialysis (15.5%) and just one patient had renal transplantation (1.5%).</s><s xml:id="_6veUZGR">Regarding cardiovascular outcomes, 6 patients had heart attack (9.2%), 3 patients had Table 2. Correlations between serum zonulin and renal, glycemic, lipid, inflammatory and body composition parameters.</s><s xml:id="_U8qR372">R (p) N = 86 eGFR (ml/min/1.73</s><s xml:id="_TAZH9pe">m 2 ) 0.222 (0.040) Creatinine (mg/dL) -0.171 (0.116) Albuminuria (mg/L) -0.243 (0.024) Fasting glucose (mg/dL) 0.136 (0.211) HbA1c (%) 0.045 (0.681) HOMA-IR -0.018 (0.873) Total Cholesterol (mg/dL) 0.229 (0.034) HDL-Cholesterol (mg/dL) -0.117 (0.285) LDL-Cholesterol (mg/dL) 0.258 (0.021) Triglycerides (mg/dL) 0.102 (0.384) IL-6 (pg/mL) -0.180 (0.099) hsCRP (mg/dL) -0.135 (0.220) BMI (kg/m 2 ) -0.198 (0.067) Body fat (%) -0.271 (0.014) Lean mass (kg) 0.182 (0.102) Free fat mass (kg) 0.178 (0.109) Total body water (kg) 0.173 (0.121) BMI: Body mass index; DM: Diabetes mellitus; eGFR: Estimated glomerular filtration rate; HbA1c: Glycated hemoglobin; hsCRP: High sensitivity C-reactive protein; IL-6: Interleukin-6.</s><s xml:id="_erQwz2U"><ref type="url" target="https://doi.org/10.1371/journal.pone.0253501.t002">https://doi.org/10.1371/journal.pone.0253501.t002</ref></s><s xml:id="_xseVUvV">stroke (4.6%), 7 patients performed any cardiovascular surgery (10.8%) and 9 patients died (13.8%).</s></p><p xml:id="_6upp9qw"><s xml:id="_CnyDKEY">Patients who presented renal outcomes had lower zonulin levels (P = 0.007), as shown in Table <ref type="table">3</ref>.</s><s xml:id="_ek6mNrt">In the multivariate logistic regression analysis, zonulin levels [OR 0.99 (0.98-0.99,</s><s xml:id="_JjezvxK">P = 0.012)] and hypertension [OR 0.07 (0.01-0.62,</s><s xml:id="_8Tz2zcc">P = 0.017)] were independently associated to renal outcomes, after adjustment for T2DM, dyslipidemia, smoking, obesity, and age.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vzqdT33">Discussion</head><p xml:id="_Xh3SjzH"><s xml:id="_QjVCw7K">In the present study, patients with T2DM and normal renal function presented elevated levels of zonulin.</s><s xml:id="_FYaT5ZX">On the other hand, patients with compromised renal function, represented by eGFR &lt; 60mL/min/1.73m 2 , had lower zonulin levels.</s><s xml:id="_76cjfu8">Correlations of zonulin with renal function, body fat percentage and lipid profile were also found in the present study.</s></p><p xml:id="_bxbdYCj"><s xml:id="_Xbabeae">It has been documented that T2DM patients present higher zonulin levels than non-diabetic subjects <ref type="bibr" target="#b19">[20,</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref>.</s><s xml:id="_GWcXCcE">This evidence was observed in different stages of the disease.</s><s xml:id="_zX24brj">Even in pre-diabetes condition, zonulin concentration were reported to be increased <ref type="bibr" target="#b26">[27]</ref>.</s><s xml:id="_3hhc9zC">In newlydiagnosed <ref type="bibr" target="#b19">[20]</ref> and longstanding T2DM patients <ref type="bibr" target="#b25">[26]</ref>, zonulin levels were also elevated, when compared to healthy subjects.</s><s xml:id="_jztGqrW">The zonulin increment may indicates a higher intestinal permeability in T2DM, since previous evidence describes zonulin as intestinal permeability marker in diabetes <ref type="bibr" target="#b28">[29]</ref>.</s></p><p xml:id="_TDVhcEU"><s xml:id="_jSqP9uG">However, the role of zonulin as a marker of intestinal permeability in kidney disease is controversial.</s><s xml:id="_nJyYum2">In the present study, lower zonulin was found in advanced DKD patients when compared to T2DM controls, but values were similar to the non-T2DM group.</s><s xml:id="_BR68ZwP">Moreover, when eGFR decreases, the zonulin also decreases, as demonstrated by the positive correlation between these parameters.</s><s xml:id="_dhSdbjQ">This finding was different than expected.</s><s xml:id="_ascqHFF">The main hypothesis of this study was that serum zonulin could be a marker of intestinal permeability in DKD, being elevated in this condition, since CKD presents permeability impairment <ref type="bibr" target="#b29">[30]</ref>.</s><s xml:id="_amcpe7p">However, previous studies <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref> present distinct results, in both directions.</s></p><p xml:id="_JDAEXXU"><s xml:id="_uR5zpZf">Similar to our findings, Hasslacher et al. <ref type="bibr" target="#b25">[26]</ref> reported a positive correlation between zonulin levels and eGFR and a negative one with albuminuria in T2DM patients.</s><s xml:id="_KXxWMbn">The positive association between zonulin and eGFR were also observed in a sample of heart failure patients <ref type="bibr" target="#b34">[35]</ref>, reinforcing that the decrease in renal function is followed by a decrease in serum zonulin.</s><s xml:id="_hkttgfU">In addition, there are evidences that pre-dialysis <ref type="bibr" target="#b20">[21]</ref> and post-renal transplantation patients <ref type="bibr" target="#b30">[31]</ref> have lower zonulin levels than controls.</s><s xml:id="_GND29ZK">Some authors suggest that zonulin may be depleted in the kidneys due to renal failure <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b34">35]</ref>.</s></p><p xml:id="_tjVy8Vd"><s xml:id="_4jXDJhh">Table 3. Association between zonulin (log) and renal, cardiovascular and death outcomes.</s><s xml:id="_hFyEFPY">Patients (n = 65) Zonulin p Renal outcomes 0.007 Yes (n = 30) 4.27 ± 0.50 No 4.64 ± 0.57 Cardiovascular outcomes 0.204 Yes (n = 16) 4.31 ± 0.47 No 4.52 ± 0.59 Death 0.060 Yes (n = 9) 4.13 ± 0.40 No 4.52 ± 0.58 Values are expressed in mean ± standard deviation.</s><s xml:id="_jbVMtpN"><ref type="url" target="https://doi.org/10.1371/journal.pone.0253501.t003">https://doi.org/10.1371/journal.pone.0253501.t003</ref></s></p><p xml:id="_DexNqG2"><s xml:id="_7zA8DSx">On the other hand, there are also evidence of a negative correlation between zonulin and eGFR, demonstrating that when renal function declines, zonulin could increase <ref type="bibr" target="#b32">[33]</ref>.</s><s xml:id="_T6RWk8v">Moreover, a study with T2DM with advanced renal disease found higher zonulin levels than controls, as well as lipopolysaccharide (LPS) and trimethylamine-N-Oxide (TMAO) <ref type="bibr" target="#b33">[34]</ref>.</s><s xml:id="_b2QyHyA">In hemodialysis patients, zonulin levels were higher than healthy individuals <ref type="bibr" target="#b31">[32]</ref> and pre-dialysis patients <ref type="bibr" target="#b32">[33]</ref>.</s><s xml:id="_UgeAQ2K">In this case, it was hypothesized that less renal elimination increases serum zonulin <ref type="bibr" target="#b31">[32]</ref>.</s></p><p xml:id="_cSFcB6p"><s xml:id="_BwHUE3w">It is suggested that zonulin may have other function in CKD, that not intestinal permeability.</s><s xml:id="_hagG58h">A systematic review showed conflicting results with respect to permeability assessment methods in CKD.</s><s xml:id="_vk3dG7x">The authors conclude that CKD patients have impaired intestinal permeability; however, data interpretation should be cautious, and new markers which do not have renal influence or gut bacteria are necessary <ref type="bibr" target="#b35">[36]</ref>.</s><s xml:id="_vfuHauQ">In the same way, it was previously documented that constipation is associated with increased uremic toxins that impacts on intestinal permeability <ref type="bibr" target="#b36">[37]</ref>.</s><s xml:id="_39Fs6Uu">However, zonulin levels were not different among peritoneal dialysis patients according to the presence of constipation <ref type="bibr" target="#b37">[38]</ref>.</s><s xml:id="_7n5XaM4">Moreover, after an intervention with prebiotics, zonulin levels did not change despite the reduction of the p-cresyl uremic toxin <ref type="bibr" target="#b38">[39]</ref>.</s><s xml:id="_hMQb9Vr">These findings are in agreement with the hypothesis that zonulin may have other function in CKD.</s></p><p xml:id="_QYwB94q"><s xml:id="_fBxpeqd">In the present study, lower zonulin concentrations were observed in patients who presented renal outcomes, such as renal function decline and hemodialysis after 5 years study inclusion.</s><s xml:id="_XvNxkkc">Moreover, zonulin levels were an independently preditor of renal outcomes.</s><s xml:id="_AkVUPt4">A hypothesis for the possible mechanism is the increase in renal glomerular permeability, with increase in albuminuria, allowing zonulin entrance, and impacting in renal health.</s><s xml:id="_NXRwUkf">It is in agreement with the negative correlation found in this study between zonulin and albuminuria.</s></p><p xml:id="_uTtNaEf"><s xml:id="_MjPHqcG">In this context, zonulin could be a predictor of DKD progression and not an intestinal permeability marker.</s><s xml:id="_TfXtg7Z">Poor outcomes were previously associated to lower zonulin levels in other conditions.</s><s xml:id="_KvE9czW">A study evaluating intestine integrity in HIV patients showed that higher zonulin levels seem to predict survival <ref type="bibr" target="#b39">[40]</ref>.</s><s xml:id="_v8unseZ">Still, when measuring cardiovascular and all causes mortality related markers, a study with heart failure patients demonstrated that lower zonulin levels could point to worst prognosis <ref type="bibr" target="#b34">[35]</ref>.</s></p><p xml:id="_Dx88dxJ"><s xml:id="_utTw3Hf">In obesity, zonulin has been studied as a marker of intestinal permeability <ref type="bibr" target="#b17">[18]</ref>.</s><s xml:id="_GEgWQma">Some studies observed higher zonulin levels in obese patients, according to body mass index <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b40">41]</ref>.</s><s xml:id="_9uy6tuu">Even so, its increment could be an independent risk factor for overweight and obesity <ref type="bibr" target="#b41">[42]</ref>.</s><s xml:id="_e8Cy8hZ">Nonetheless, data evaluating zonulin levels and body composition is scarce.</s><s xml:id="_K7r4XKF">Our findings show a controversial association, where higher zonulin levels were correlated to less body fat.</s><s xml:id="_QcmU2AN">However, this data should be carefully interpretated, considering that our sample was mainly represented by DKD patients.</s></p><p xml:id="_wbz5qWW"><s xml:id="_jAuRzvr">According to serum lipid evaluation, there was also a positive correlation between zonulin and total cholesterol and LDL, which is in agreement to the literature.</s><s xml:id="_r47GeGb">Previous studies reported the association of zonulin with triglyceride and total cholesterol <ref type="bibr" target="#b19">[20,</ref><ref type="bibr" target="#b40">41]</ref>.</s><s xml:id="_CGeCKm6">Moreover, higher zonulin levels were also associated with hyperlipidemia <ref type="bibr" target="#b41">[42]</ref>.</s><s xml:id="_4jB2zKx">This association could be explained due to the communication between the gut and adipose tissue <ref type="bibr" target="#b42">[43]</ref>.</s></p><p xml:id="_zfGK6CM"><s xml:id="_8aJXJs4">This study has some limitations, such as the lack about urinary zonulin values.</s><s xml:id="_9YmDBVU">Furthermore, the sample size is relatively small, however we had power for study conduction, based on previous sample size calculation.</s><s xml:id="_ruhNEQS">This is the first study assessing serum zonulin levels in renal complications of T2DM in Brazilian subjects, with evaluation of major outcomes.</s><s xml:id="_QsrGg4y">Serum zonulin seems to be an impaired intestinal permeability marker in T2DM patients with normal renal function.</s><s xml:id="_Kb5aTFw">Nevertheless, DKD impact in zonulin levels is not totally elucidated.</s><s xml:id="_jKqNwQB">Further studies are necessary to investigate the association of zonulin in DKD and explore its use as a marker of intestinal permeability or the disease progression.</s><s xml:id="_mVheUKd">In addition, we suggest different intestinal permeability assessment markers in DKD, for further clarification.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig 1 .</head><label>1</label><figDesc><div><p xml:id="_4JBdrwa"><s xml:id="_69eCfTk">T2DM controls showed higher zonulin levels than non-T2DM controls [(131.35</s><s xml:id="_p7A8ggS">(83.0-170.5)</s><s xml:id="_T37xK4f">vs. 87.25 (54.7-111.8);</s><s xml:id="_JMg7HBp">P = 0.018] and advanced DKD cases [63.72 (45.03-106.0);</s><s xml:id="_wx3hJSu">P = 0.007].</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig 1 .</head><label>1</label><figDesc><div><p xml:id="_SXztJJH"><s xml:id="_SeuTQSZ">Fig 1. Serum zonulin levels among groups.</s><s xml:id="_9888jYW">Serum zonulin levels are expressed in median among different study groups.</s><s xml:id="_DtwCrqR">Values in bold indicate p&lt;0.05.</s><s xml:id="_cwPEcCH">T2DM: Type 2 diabetes mellitus; DKD: Diabetic kidney disease.</s><s xml:id="_yNPSTx4">https://doi.org/10.1371/journal.pone.0253501.g001</s></p></div></figDesc><graphic coords="5,200.01,78.01,338.12,198.43" type="bitmap" /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_z7QwmDZ"><s xml:id="_VNphjTc">PLOS ONE | https://doi.org/10.1371/journal.pone.0253501</s><s xml:id="_WuTGQXB">June 25, 2021</s></p></note>
		</body>
		<back>

			<div type="funding">
<div xml:id="_6tuahwM"><p xml:id="_xds6cZT"><s xml:id="_KNpUGUB">This study was supported by grants from <rs type="funder">Conselho Nacional de Desenvolvimento Cientı ´fico e Tecnolo ´gico</rs> (<rs type="funder">CNPq</rs> -<ref type="url" target="www.cnpq.br">www.cnpq.br</ref>)</s><s xml:id="_HJMShmx">and <rs type="funder">Fundo de Incentivo à Pesquisa e Eventos</rs> (<rs type="grantNumber">FIPE 2018-0421</rs>) at the <rs type="funder">Hospital de Clı ´nicas de Porto Alegre</rs> (<ref type="url" target="http://www.hcpa.edu.br">www.  hcpa.edu.br</ref>).</s><s xml:id="_BwbzS5t">The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_JA5nt9y">
					<idno type="grant-number">FIPE 2018-0421</idno>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_XAdhyZ2"><p xml:id="_3z66HXB"><s xml:id="_AYdvpVP">All relevant data are within the manuscript and its Supporting Information files.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_nUkyqKA">Supporting information</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_FQNHUR7">S1 Data. (SAV)</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_FTsymN4">Author Contributions</head><p xml:id="_VQJMVTz"><s xml:id="_pDekAmk">Conceptualization: Larissa Salomoni Carpes, Bruna Bellincanta Nicoletto, Jakeline Rheinhemer, Gabriela Corrêa Souza.</s></p><p xml:id="_RycmM84"><s xml:id="_n7j3R6F">Data curation: Larissa Salomoni Carpes, Bruna Bellincanta Nicoletto.</s></p><p xml:id="_Ez9Azge"><s xml:id="_RM5yzyJ">Formal analysis: Larissa Salomoni Carpes, Bruna Bellincanta Nicoletto, Daisy Crispim, Gabriela Corrêa Souza.</s></p><p xml:id="_GUAXxK7"><s xml:id="_WKn3aux">Funding acquisition: Luis Henrique Canani, Daisy Crispim, Gabriela Corrêa Souza.</s></p><p xml:id="_eFyquBA"><s xml:id="_acfnZuF">Investigation: Larissa Salomoni Carpes, Bruna Bellincanta Nicoletto, Daisy Crispim.</s></p><p xml:id="_tBbXDE2"><s xml:id="_HrumxAJ">Methodology: Larissa Salomoni Carpes, Bruna Bellincanta Nicoletto, Jakeline Rheinhemer, Daisy Crispim, Gabriela Corrêa Souza.</s></p><p xml:id="_MVNqNUS"><s xml:id="_X2wy3UB">Project administration: Larissa Salomoni Carpes, Daisy Crispim, Gabriela Corrêa Souza.</s></p><p xml:id="_8BXPpjK"><s xml:id="_d3aNQZD">Resources: Daisy Crispim, Gabriela Corrêa Souza.</s></p><p xml:id="_2YUz66x"><s xml:id="_23Dxfsr">Supervision: Gabriela Corrêa Souza.</s></p><p xml:id="_XFVT64B"><s xml:id="_VU6T7gF">Visualization: Larissa Salomoni Carpes, Bruna Bellincanta Nicoletto, Daisy Crispim, Gabriela Corrêa Souza.</s></p><p xml:id="_22mYm4y"><s xml:id="_5bHzCXT">Writing -original draft: Larissa Salomoni Carpes, Bruna Bellincanta Nicoletto, Gabriela Corrêa Souza.</s></p><p xml:id="_CQ9DHnS"><s xml:id="_kUFWPH2">Writing -review &amp; editing: Larissa Salomoni Carpes, Bruna Bellincanta Nicoletto, Luis Henrique Canani, Daisy Crispim, Gabriela Corrêa Souza.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_DFxHK6s">Gut Microbiota in Cardiovascular Health and Disease</title>
		<author>
			<persName><forename type="first">Whw</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kitai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Hazen</surname></persName>
		</author>
		<idno type="DOI">10.1161/circresaha.117.309715</idno>
		<idno type="PMID">28360349</idno>
		<ptr target="https://doi.org/10.1161/CIRCRESAHA.117.309715" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZRTjGQn">Circ Res</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="1183" to="1196" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tang WHW, Kitai T, Hazen SL. Gut Microbiota in Cardiovascular Health and Disease. Circ Res 2017; 120:1183-96. https://doi.org/10.1161/CIRCRESAHA.117.309715 PMID: 28360349</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_7ZGSsUX">Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease</title>
		<author>
			<persName><forename type="first">D</forename><surname>Mafra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lobo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Barros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Koppe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Vaziri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Fouque</surname></persName>
		</author>
		<idno type="DOI">10.2217/fmb.13.165</idno>
		<ptr target="https://doi.org/10.2217/fmb.13.165PMID:24762311" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_9z8zrzu">Future Microbiol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="399" to="410" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mafra D, Lobo JC, Barros AF, Koppe L, Vaziri ND, Fouque D. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease. Future Microbiol 2014; 9:399-410. https://doi.org/10.2217/fmb.13.165 PMID: 24762311</note>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m" type="main" xml:id="_p2Yhypc">Impact of altered intestinal microbiota on chronic kidney disease progression</title>
		<author>
			<persName><forename type="first">E</forename><surname>Castillo-Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fernandez-Prado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Esteras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Perez-Gomez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gracia-Iguacel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Fernandez-Fernandez</surname></persName>
		</author>
		<idno type="DOI">10.3390/toxins10070300</idno>
		<ptr target="https://doi.org/10.3390/toxins10070300PMID:30029499" />
		<imprint>
			<date type="published" when="2018">2018</date>
			<publisher>Multidisciplinary Digital Publishing Institute</publisher>
			<biblScope unit="volume">10</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Castillo-Rodriguez E, Fernandez-Prado R, Esteras R, Perez-Gomez MV, Gracia-Iguacel C, Fernan- dez-Fernandez B, et al. Impact of altered intestinal microbiota on chronic kidney disease progression. vol. 10. Multidisciplinary Digital Publishing Institute; 2018. https://doi.org/10.3390/toxins10070300 PMID: 30029499</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_vHsGVT4">Expansion of Urease-and Uricase-Containing, Indole-and p-Cresol-Forming and Contraction of Short-Chain Fatty Acid-Producing Intestinal Microbiota in ESRD</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Piceno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">Z</forename><surname>Desantis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Andersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Vaziri</surname></persName>
		</author>
		<idno type="DOI">10.1159/000360010</idno>
		<ptr target="https://doi.org/10.1159/000360010PMID:24643131" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_yZUwjHS">Am J Nephrol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="230" to="237" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of Urease-and Uri- case-Containing, Indole-and p-Cresol-Forming and Contraction of Short-Chain Fatty Acid-Producing Intestinal Microbiota in ESRD. Am J Nephrol 2014; 39:230-7. https://doi.org/10.1159/000360010 PMID: 24643131</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_a9B6U9r">Gut microbiome in chronic kidney disease: challenges and opportunities</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nallu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ramezani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Muralidharan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Raj</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.trsl.2016.04.007</idno>
		<idno type="PMID">27187743</idno>
		<ptr target="https://doi.org/10.1016/j.trsl.2016.04.007" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_JzYuMNw">Transl Res</title>
		<imprint>
			<biblScope unit="volume">179</biblScope>
			<biblScope unit="page" from="24" to="37" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nallu A, Sharma S, Ramezani A, Muralidharan J, Raj D. Gut microbiome in chronic kidney disease: challenges and opportunities. Transl Res 2017; 179:24-37. https://doi.org/10.1016/j.trsl.2016.04.007 PMID: 27187743</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_bddRycG">Protein-Bound Uremic Toxins from Gut Microbiota and Inflammatory Markers in Chronic Kidney Disease</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Borges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Barros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Nakao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Dolenga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Fouque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mafra</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.jrn.2016.07.005</idno>
		<idno type="PMID">27751361</idno>
		<ptr target="https://doi.org/10.1053/j.jrn.2016.07.005" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_cfEKQFD">J Ren Nutr</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="396" to="400" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Borges NA, Barros AF, Nakao LS, Dolenga CJ, Fouque D, Mafra D. Protein-Bound Uremic Toxins from Gut Microbiota and Inflammatory Markers in Chronic Kidney Disease. J Ren Nutr 2016; 26:396-400. https://doi.org/10.1053/j.jrn.2016.07.005 PMID: 27751361</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_UFRWFW6">Gut Microbiota in Health and Disease</title>
		<author>
			<persName><forename type="first">I</forename><surname>Sekirov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lcm</forename><surname>Antunes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Finlay</surname></persName>
		</author>
		<idno type="DOI">10.1152/physrev.00045.2009</idno>
		<ptr target="https://doi.org/10.1152/physrev.00045.2009PMID:20664075" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_8XygXAu">Physiol Rev</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="859" to="904" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut Microbiota in Health and Disease. Physiol Rev 2010; 90:859-904. https://doi.org/10.1152/physrev.00045.2009 PMID: 20664075</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_NeA88SZ">The intestinal barrier: a fundamental role in health and disease</title>
		<author>
			<persName><forename type="first">M</forename><surname>Vancamelbeke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vermeire</surname></persName>
		</author>
		<idno type="DOI">10.1080/17474124.2017.1343143</idno>
		<idno type="PMID">28650209</idno>
		<ptr target="https://doi.org/10.1080/17474124.2017.1343143" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_cChvkgj">Expert Rev Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="821" to="834" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vancamelbeke M, Vermeire S. The intestinal barrier: a fundamental role in health and disease. Expert Rev Gastroenterol Hepatol 2017; 11:821-34. https://doi.org/10.1080/17474124.2017.1343143 PMID: 28650209</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_p9G9FYF">Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Fasano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Not</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Uzzau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Berti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tommasini</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736%2800%2902169-3</idno>
		<ptr target="https://doi.org/10.1016/S0140-6736(00)02169-3PMID:10801176" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_ekxSU7E">Lancet</title>
		<imprint>
			<biblScope unit="volume">355</biblScope>
			<biblScope unit="page" from="1518" to="1519" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fasano A, Not T, Wang W, Uzzau S, Berti I, Tommasini A, et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet 2000; 355:1518-9. https://doi. org/10.1016/S0140-6736(00)02169-3 PMID: 10801176</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_VQ253qK">Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation, Autoimmunity, and Cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Fasano</surname></persName>
		</author>
		<idno type="DOI">10.1152/physrev.00003.2008</idno>
		<ptr target="https://doi.org/10.1152/physrev.00003.2008PMID:21248165" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_kySFcNm">Physiol Rev</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="151" to="175" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fasano A. Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation, Autoimmunity, and Cancer. Physiol Rev 2011; 91:151-75. https://doi.org/10.1152/physrev.00003.2008 PMID: 21248165</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_m9GNYvm">Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases</title>
		<author>
			<persName><forename type="first">C</forename><surname>Sturgeon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fasano</surname></persName>
		</author>
		<idno type="DOI">10.1080/21688370.2016.1251384</idno>
		<idno type="PMID">28123927</idno>
		<ptr target="https://doi.org/10.1080/21688370.2016.1251384" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_arEvvk5">Tissue Barriers</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">1251384</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sturgeon C, Fasano A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers 2016; 4:e1251384. https://doi.org/10. 1080/21688370.2016.1251384 PMID: 28123927</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_yg7c7HG">Association between increased intestinal permeability and disease: A systematic review</title>
		<author>
			<persName><forename type="first">B</forename><surname>Leech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schloss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Steel</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.aimed.2018.08.003</idno>
		<ptr target="https://doi.org/10.1016/j.aimed.2018.08.003" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_cFcR8ke">Adv Integr Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="23" to="34" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Leech B, Schloss J, Steel A. Association between increased intestinal permeability and disease: A sys- tematic review. Adv Integr Med 2019; 6:23-34. https://doi.org/10.1016/j.aimed.2018.08.003</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_Gyj45qh">Risk factors associated with intestinal permeability in an adult population: A systematic review</title>
		<author>
			<persName><forename type="first">B</forename><surname>Leech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mcintyre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Steel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sibbritt</surname></persName>
		</author>
		<idno type="DOI">10.1111/ijcp.13385</idno>
		<ptr target="https://doi.org/10.1111/ijcp.13385PMID:31243854" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_dPDmSWw">Int J Clin Pract</title>
		<imprint>
			<biblScope unit="page" from="1" to="26" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Leech B, McIntyre E, Steel A, Sibbritt D. Risk factors associated with intestinal permeability in an adult population: A systematic review. Int J Clin Pract 2019:1-26. https://doi.org/10.1111/ijcp.13385 PMID: 31243854</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_Hqwmh5h">Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Barbaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cremon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Morselli-Labate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Sabatino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Giuffrida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Corazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename></persName>
		</author>
		<idno type="DOI">10.1136/gutjnl-2019-319281</idno>
		<ptr target="https://doi.org/10.1136/gutjnl-2019-319281PMID:32060130" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_5smCG8Z">Gut</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="1966" to="1974" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Barbaro MR, Cremon C, Morselli-Labate AM, Di Sabatino A, Giuffrida P, Corazza GR, et al. Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity. Gut 2020; 69:1966-74. https:// doi.org/10.1136/gutjnl-2019-319281 PMID: 32060130</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_gRQbEfc">Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D</title>
		<author>
			<persName><forename type="first">P</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Silvester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Sawhney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Rangan</surname></persName>
		</author>
		<idno type="DOI">10.1177/2050640619826419</idno>
		<ptr target="https://doi.org/10.1177/2050640619826419PMID:31210949" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_HsD3qFJ">United Eur Gastroenterol J</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="709" to="715" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Singh P, Silvester J, Chen X, Xu H, Sawhney V, Rangan V, et al. Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D. United Eur Gastroenterol J 2019; 7:709-15. https://doi.org/10. 1177/2050640619826419 PMID: 31210949</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_RHsqBUP">Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Ciccia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Guggino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rizzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alessandro</forename><forename type="middle">R</forename><surname>Luchetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Milling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2016-210000</idno>
		<ptr target="https://doi.org/10.1136/annrheumdis-2016-210000PMID:28069576" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_VQqYczN">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="1123" to="1132" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ciccia F, Guggino G, Rizzo A, Alessandro R, Luchetti MM, Milling S, et al. Dysbiosis and zonulin upre- gulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. Ann Rheum Dis 2017; 76:1123-32. https://doi.org/10.1136/annrheumdis-2016-210000 PMID: 28069576</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_7Ff5pEK">Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis</title>
		<author>
			<persName><forename type="first">N</forename><surname>Tajik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Frech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Schulz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Scha ¨lter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lucas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Azizov</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41467-020-15831-7</idno>
		<ptr target="https://doi.org/10.1038/s41467-020-15831-7PMID:32332732" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_g4SCGQG">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">1995</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tajik N, Frech M, Schulz O, Scha ¨lter F, Lucas S, Azizov V, et al. Targeting zonulin and intestinal epithe- lial barrier function to prevent onset of arthritis. Nat Commun 2020; 11:1995. https://doi.org/10.1038/ s41467-020-15831-7 PMID: 32332732</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_BS3Nj9e">Zonulin Concentration in Obese and Normal Weight Subjects</title>
		<author>
			<persName><forename type="first">Zak-Golab A</forename><surname>Piotr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Aptekorz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zientara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Juszczyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Martirosian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
		<idno type="DOI">10.1155/2013/674106</idno>
		<ptr target="https://doi.org/10.1155/2013/674106PMID:23970898" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_ERcDWJz">Int J Endocrinol</title>
		<imprint>
			<biblScope unit="volume">2013</biblScope>
			<biblScope unit="page" from="1" to="9" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zak-Golab A, Piotr K, Aptekorz M, Zientara M, Juszczyk L, Martirosian G, et al. Zonulin Concentration in Obese and Normal Weight Subjects. Int J Endocrinol 2013; 2013:1-9. https://doi.org/10.1155/2013/ 674106 PMID: 23970898</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_589534H">Is There an Association Between Atherosclerotic Burden, Oxidative Stress, and Gut-Derived Lipopolysaccharides?</title>
		<author>
			<persName><forename type="first">L</forename><surname>Loffredo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Ivanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ciobanu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Deseatnicova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gutu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mudrea</surname></persName>
		</author>
		<idno type="DOI">10.1089/ars.2020.8109</idno>
		<ptr target="https://doi.org/10.1089/ars.2020.8109PMID:32336107" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_FDpa3gY">Antioxid Redox Signal</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="761" to="766" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Loffredo L, Ivanov V, Ciobanu N, Deseatnicova E, Gutu E, Mudrea L, et al. Is There an Association Between Atherosclerotic Burden, Oxidative Stress, and Gut-Derived Lipopolysaccharides? Antioxid Redox Signal 2020; 33:761-6. https://doi.org/10.1089/ars.2020.8109 PMID: 32336107</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_da9PUQK">Circulating zonulin levels in newly diagnosed Chinese type 2 diabetes patients</title>
		<author>
			<persName><forename type="first">D</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Yue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zeng</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.diabres.2014.08.017</idno>
		<idno type="PMID">25238913</idno>
		<ptr target="https://doi.org/10.1016/j.diabres.2014.08.017" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_RgySreF">Diabetes Res Clin Pract</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="312" to="318" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhang D, Zhang L, Zheng Y, Yue F, Russell RD, Zeng Y. Circulating zonulin levels in newly diagnosed Chinese type 2 diabetes patients. Diabetes Res Clin Pract 2014; 106:312-8. https://doi.org/10.1016/j. diabres.2014.08.017 PMID: 25238913</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_Ntsw2qM">Zonulin, inflammation and iron status in patients with early stages of chronic kidney disease</title>
		<author>
			<persName><forename type="first">E</forename><surname>Lukaszyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lukaszyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Koc-Zorawska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bodzenta-Lukaszyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Malyszko</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11255-017-1741-5</idno>
		<ptr target="https://doi.org/10.1007/s11255-017-1741-5PMID:29134616" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_FY9Fkgg">Int Urol Nephrol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="121" to="125" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lukaszyk E, Lukaszyk M, Koc-Zorawska E, Bodzenta-Lukaszyk A, Malyszko J. Zonulin, inflammation and iron status in patients with early stages of chronic kidney disease. Int Urol Nephrol 2017; 50:121-5. https://doi.org/10.1007/s11255-017-1741-5 PMID: 29134616</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_4fTTRMW">Serum and urinary progranulin in diabetic kidney disease</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Nicoletto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Krolikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Crispim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Canani</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0165177</idno>
		<idno type="PMID">27776152</idno>
		<ptr target="https://doi.org/10.1371/journal.pone.0165177" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_TtNAWUN">PLoS One</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">165177</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nicoletto BB, Krolikowski TC, Crispim D, Canani LH. Serum and urinary progranulin in diabetic kidney disease. PLoS One 2016; 11:e0165177. https://doi.org/10.1371/journal.pone.0165177 PMID: 27776152</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_RU8ECdx">Classification and Diagnosis of Diabetes</title>
		<author>
			<persName><forename type="first">American</forename><surname>Diabetes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Association</forename></persName>
		</author>
		<idno type="DOI">10.2337/dc17-s005</idno>
		<ptr target="https://doi.org/10.2337/dc17-S005PMID:27979889" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_rGaGWUb">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="11" to="24" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care 2017; 40: S11-24. https://doi.org/10.2337/dc17-S005 PMID: 27979889</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_4RfutNQ">A New Equation to Estimate Glomerular Filtration Rate</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Levey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y (</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">)</forename><surname>Lucy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Castro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">I</forename><surname>Feldman</surname></persName>
		</author>
		<idno type="DOI">10.7326/0003-4819-150-9-200905050-00006</idno>
		<ptr target="https://doi.org/10.7326/0003-4819-150-9-200905050-00006PMID:19414839" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_ecVJbxR">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="page">604</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Levey AS, Stevens LA, Schmid CH, Zhang Y (Lucy), Castro AF, Feldman HI, et al. A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med 2009; 150:604. https://doi.org/10.7326/0003- 4819-150-9-200905050-00006 PMID: 19414839</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_XnX42NG">Bioelectrical impedance analysis-Part II: Utilization in clinical practice</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">G</forename><surname>Kyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bosaeus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Lorenzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Deurenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Elia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Go</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.clnu.2004.09.012</idno>
		<idno type="PMID">15556267</idno>
		<ptr target="https://doi.org/10.1016/j.clnu.2004.09.012" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_F6sgqgF">Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1430" to="1453" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Go ´mez JM, et al. Bioelectrical impedance analysis-Part II: Utilization in clinical practice. Clin Nutr 2004; 23:1430-53. https://doi.org/10.1016/j. clnu.2004.09.012 PMID: 15556267</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_HGSEma6">Serum zonulin as parameter of intestinal permeability in longstanding type 2 diabetes: correlations with metabolism parameter and renal function. J Diabetes</title>
		<author>
			<persName><forename type="first">C</forename><surname>Hasslacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Kulozik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Platten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kraft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Siegel</surname></persName>
		</author>
		<idno type="DOI">10.15406/jdmdc.2018.05.00138</idno>
		<ptr target="https://doi.org/10.15406/jdmdc.2018.05.00138" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_qfVVGzH">Metab Disord Control</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="58" to="62" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hasslacher C, Kulozik F, Platten I, Kraft M, Siegel E. Serum zonulin as parameter of intestinal perme- ability in longstanding type 2 diabetes: correlations with metabolism parameter and renal function. J Dia- betes, Metab Disord Control 2018; 5:58-62. https://doi.org/10.15406/jdmdc.2018.05.00138</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_ptcDr8y">Low-grade endotoxemia, gut permeability and platelet activation in patients with impaired fasting glucose</title>
		<author>
			<persName><forename type="first">R</forename><surname>Carnevale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pastori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Nocella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Cammisotto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Baratta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Ben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.numecd.2017.06.007</idno>
		<idno type="PMID">28743559</idno>
		<ptr target="https://doi.org/10.1016/j.numecd.2017.06.007" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_JqZTv84">Nutr Metab Cardiovasc Dis</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="890" to="895" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Carnevale R, Pastori D, Nocella C, Cammisotto V, Baratta F, Del Ben M, et al. Low-grade endotoxemia, gut permeability and platelet activation in patients with impaired fasting glucose. Nutr Metab Cardiovasc Dis 2017; 27:890-5. https://doi.org/10.1016/j.numecd.2017.06.007 PMID: 28743559</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_gpWTqNy">Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes</title>
		<author>
			<persName><forename type="first">B</forename><surname>Jayashree</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Bibin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Prabhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Shanthirani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gokulakrishnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Lakshmi</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11010-013-1911-4</idno>
		<ptr target="https://doi.org/10.1007/s11010-013-1911-4PMID:24347174" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_awyBKc8">Mol Cell Biochem</title>
		<imprint>
			<biblScope unit="volume">388</biblScope>
			<biblScope unit="page" from="203" to="210" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jayashree B, Bibin YS, Prabhu D, Shanthirani CS, Gokulakrishnan K, Lakshmi BS, et al. Increased cir- culatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem 2014; 388:203-10. https://doi.org/10.1007/s11010- 013-1911-4 PMID: 24347174</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_vPNUxwS">Plasma zonulin levels as a noninvasive biomarker of intestinal permeability in women with gestational diabetes mellitus</title>
		<author>
			<persName><forename type="first">E</forename><surname>Demir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ozkan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Seckin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sahtiyancı</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Demir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Tabak</surname></persName>
		</author>
		<idno type="DOI">10.3390/biom9010024</idno>
		<idno type="PMID">30641999</idno>
		<ptr target="https://doi.org/10.3390/biom9010024" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_CnuJEKb">Biomolecules</title>
		<imprint>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Demir E, Ozkan H, Seckin KD, Sahtiyancı B, Demir B, Tabak O, et al. Plasma zonulin levels as a non- invasive biomarker of intestinal permeability in women with gestational diabetes mellitus. Biomolecules 2019. https://doi.org/10.3390/biom9010024 PMID: 30641999</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_hwXbvTG">Alterations of intestinal barrier and microbiota in chronic kidney disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sabatino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Regolisti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Brusasco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cabassi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Morabito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fiaccadori</surname></persName>
		</author>
		<idno type="DOI">10.1093/ndt/gfu287</idno>
		<ptr target="https://doi.org/10.1093/ndt/gfu287PMID:25190600" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_fpTaZYv">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="924" to="933" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sabatino A, Regolisti G, Brusasco I, Cabassi A, Morabito S, Fiaccadori E. Alterations of intestinal barrier and microbiota in chronic kidney disease. Nephrol Dial Transplant 2015; 30:924-33. https://doi.org/10. 1093/ndt/gfu287 PMID: 25190600</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_bwNgVr3">Zonulin, iron status, and anemia in kidney transplant recipients: Are they related?</title>
		<author>
			<persName><forename type="first">J</forename><surname>Malyszko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Koc-Zorawska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Levin-Iaina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Malyszko</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.transproceed.2014.09.018</idno>
		<idno type="PMID">25380885</idno>
		<ptr target="https://doi.org/10.1016/j.transproceed.2014.09.018" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_uU5B5EV">Transplant Proc</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="2644" to="2646" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Malyszko J, Koc-Zorawska E, Levin-Iaina N, Malyszko J. Zonulin, iron status, and anemia in kidney transplant recipients: Are they related? Transplant Proc 2014; 46:2644-6. https://doi.org/10.1016/j. transproceed.2014.09.018 PMID: 25380885</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_y9NC8Jk">Relationship between plasma levels of zonulin, bacterial lipopolysaccharides, d-lactate and markers of inflammation in haemodialysis patients</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ficek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wyskida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ficek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wajda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Witkowicz</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11255-016-1495-5</idno>
		<ptr target="https://doi.org/10.1007/s11255-016-1495-5PMID:28044237" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_k5ymRYx">Int Urol Nephrol</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="717" to="725" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ficek J, Wyskida K, Ficek R, Wajda J, Klein D, Witkowicz J, et al. Relationship between plasma levels of zonulin, bacterial lipopolysaccharides, d-lactate and markers of inflammation in haemodialysis patients. Int Urol Nephrol 2017; 49:717-25. https://doi.org/10.1007/s11255-016-1495-5 PMID: 28044237</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_VhE5tMS">The relation of zonulin level to inflammation and metabolic conditions in patients with chronic kidney disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Karatas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cihan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dugeroglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Bayrak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Canakci</surname></persName>
		</author>
		<idno type="DOI">10.19193/0393-6384%5F2019%5F2%5F162</idno>
		<ptr target="https://doi.org/10.19193/0393-6384_2019_2_162" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_mT8ZeFa">Acta Medica Mediterr</title>
		<imprint>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Karatas A, Cihan M, Dugeroglu H, Kaya Y, Bayrak T, Canakci E. The relation of zonulin level to inflam- mation and metabolic conditions in patients with chronic kidney disease. Acta Medica Mediterr 2019. https://doi.org/10.19193/0393-6384_2019_2_162</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_c3MdDPp">Gut Microbiota-Dependent Trimethylamine-N-oxide and Serum Biomarkers in Patients with T2DM and Advanced CKD</title>
		<author>
			<persName><forename type="first">Mai</forename><surname>Al-Obaide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Datta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Rewers-Felkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Salguero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Al-Obaidi</surname></persName>
		</author>
		<idno type="DOI">10.3390/jcm6090086</idno>
		<ptr target="https://doi.org/10.3390/jcm6090086PMID:28925931" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_btTaCWd">J Clin Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">86</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Al-Obaide MAI, Singh R, Datta P, Rewers-Felkins KA, Salguero M V., Al-Obaidi I, et al. Gut Microbiota- Dependent Trimethylamine-N-oxide and Serum Biomarkers in Patients with T2DM and Advanced CKD. J Clin Med 2017; 6:86. https://doi.org/10.3390/jcm6090086 PMID: 28925931</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_nUQPgRU">Plasma Zonulin and its Association with Kidney Function, Severity of Heart Failure, and Metabolic Inflammation</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Dschietzig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Boschann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ruppert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">P</forename><surname>Armbruster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Meinitzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bankovic</surname></persName>
		</author>
		<idno type="DOI">10.7754/Clin.Lab.2016.160512</idno>
		<idno type="PMID">28164545</idno>
		<ptr target="https://doi.org/10.7754/Clin.Lab.2016.160512" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_rC4HXCb">Clin Lab</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="2443" to="2447" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dschietzig TB, Boschann F, Ruppert J, Armbruster FP, Meinitzer A, Bankovic D, et al. Plasma Zonulin and its Association with Kidney Function, Severity of Heart Failure, and Metabolic Inflammation. Clin Lab 2016; 62:2443-7. https://doi.org/10.7754/Clin.Lab.2016.160512 PMID: 28164545</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_yhAGQmM">Measurement of the intestinal permeability in chronic kidney disease</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Terpstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Geerlings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Bemelman</surname></persName>
		</author>
		<idno type="DOI">10.5527/wjn.v5.i4.378</idno>
		<idno type="PMID">27458567</idno>
		<ptr target="https://doi.org/10.5527/wjn.v5.i4.378" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_Sxmebkn">World J Nephrol</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Terpstra ML, Singh R, Geerlings SE, Bemelman FJ. Measurement of the intestinal permeability in chronic kidney disease. World J Nephrol 2016. https://doi.org/10.5527/wjn.v5.i4.378 PMID: 27458567</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_DgzapwK">Bowel Habits and the Association With Uremic Toxins in Non-Dialysis-Dependent Chronic Kidney Disease Patients</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">I</forename><surname>Ramos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Armani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Canziani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ribeiro</forename><surname>Dolenga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Nakao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename></persName>
		</author>
		<idno type="DOI">10.1053/j.jrn.2019.02.004</idno>
		<ptr target="https://doi.org/10.1053/j.jrn.2019.02.004PMID:30956092" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_qsewPdW">J Ren Nutr</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="31" to="35" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ramos CI, Armani RG, Canziani ME, Ribeiro Dolenga CJ, Nakao LS, Campbell KL, et al. Bowel Habits and the Association With Uremic Toxins in Non-Dialysis-Dependent Chronic Kidney Disease Patients. J Ren Nutr 2020; 30:31-5. https://doi.org/10.1053/j.jrn.2019.02.004 PMID: 30956092</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_bVVKes9">Influence of bowel habits on gut-derived toxins in peritoneal dialysis patients</title>
		<author>
			<persName><forename type="first">Nbf</forename><surname>Pereira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">I</forename><surname>Ramos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>De Andrade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Teixeira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Nakao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Rodrigues</surname></persName>
		</author>
		<idno type="DOI">10.1007/s40620-020-00819-9</idno>
		<idno type="PMID">32737690</idno>
		<ptr target="https://doi.org/10.1007/s40620-020-00819-9" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_SKhwdsa">J Nephrol</title>
		<imprint>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pereira NBF, Ramos CI, de Andrade LS, Teixeira RR, Nakao LS, Rodrigues SD, et al. Influence of bowel habits on gut-derived toxins in peritoneal dialysis patients. J Nephrol 2020. https://doi.org/10. 1007/s40620-020-00819-9 PMID: 32737690</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_eagjWKu">Effect of prebiotic (fructooligosaccharide) on uremic toxins of chronic kidney disease patients: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">I</forename><surname>Ramos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Armani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mef</forename><surname>Canziani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Dalboni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cjr</forename><surname>Dolenga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Nakao</surname></persName>
		</author>
		<idno type="DOI">10.1093/ndt/gfy171</idno>
		<ptr target="https://doi.org/10.1093/ndt/gfy171PMID:29939302" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_gXKwrTr">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1876" to="1884" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ramos CI, Armani RG, Canziani MEF, Dalboni MA, Dolenga CJR, Nakao LS, et al. Effect of prebiotic (fructooligosaccharide) on uremic toxins of chronic kidney disease patients: a randomized controlled trial. Nephrol Dial Transplant 2019; 34:1876-84. https://doi.org/10.1093/ndt/gfy171 PMID: 29939302</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_Es2G4uK">Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sinclair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Shive</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Clagett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Funderburg</surname></persName>
		</author>
		<idno type="DOI">10.1093/infdis/jiu238</idno>
		<ptr target="https://doi.org/10.1093/infdis/jiu238PMID:24755434" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_aX5tQpS">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">210</biblScope>
			<biblScope unit="page" from="1228" to="1238" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, et al. Gut epithelial barrier dys- function and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014; 210:1228-38. https://doi.org/10.1093/infdis/jiu238 PMID: 24755434</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_fbUhVD9">Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Moreno-Navarrete</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sabater</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ortega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ricart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Ferna ´ndez-Real</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0037160</idno>
		<idno type="PMID">22629362</idno>
		<ptr target="https://doi.org/10.1371/journal.pone.0037160" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_Z2uxBzZ">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Moreno-Navarrete JM, Sabater M, Ortega F, Ricart W, Ferna ´ndez-Real JM. Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance. PLoS One 2012; 7. https://doi.org/10.1371/journal.pone.0037160 PMID: 22629362</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_WxPNEGN">Higher Levels of Serum Zonulin May Rather Be Associated with Increased Risk of Obesity and Hyperlipidemia, Than with Gastrointestinal Symptoms or Disease Manifestations</title>
		<author>
			<persName><forename type="first">B</forename><surname>Ohlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Orho-Melander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Nilsson</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms18030582</idno>
		<ptr target="https://doi.org/10.3390/ijms18030582PMID:28282855" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_GHBWVgm">Int J Mol Sci</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">582</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ohlsson B, Orho-Melander M, Nilsson P. Higher Levels of Serum Zonulin May Rather Be Associated with Increased Risk of Obesity and Hyperlipidemia, Than with Gastrointestinal Symptoms or Disease Manifestations. Int J Mol Sci 2017; 18:582. https://doi.org/10.3390/ijms18030582 PMID: 28282855</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_Wd4fG57">An Okinawan-based Nordic diet improves glucose and lipid metabolism in health and type 2 diabetes, in alignment with changes in the endocrine profile, whereas zonulin levels are elevated (Review)</title>
		<author>
			<persName><forename type="first">B</forename><surname>Ohlsson</surname></persName>
		</author>
		<idno type="DOI">10.3892/etm.2019.7303</idno>
		<ptr target="https://doi.org/10.3892/etm.2019.7303PMID:30936958" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_NyDAfwa">Exp Ther Med</title>
		<imprint>
			<biblScope unit="page" from="2883" to="2893" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ohlsson B. An Okinawan-based Nordic diet improves glucose and lipid metabolism in health and type 2 diabetes, in alignment with changes in the endocrine profile, whereas zonulin levels are elevated (Review). Exp Ther Med 2019:2883-93. https://doi.org/10.3892/etm.2019.7303 PMID: 30936958</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
